IDT Biologika, a leading contract development and manufacturing organization (CDMO) specialized in viral vaccines, viral vectors for cell and gene therapy as well as oncolytic viruses and other biologics, has been selected as a winner of CDMO Leadership Awards in each of the six categories Capabilities, Compatibility, Expertise, Quality, Reliability and Service in the group of respondents “Overall”, which combines Big and Small Pharma. In addition to that, IDT Biologika also scored as 2024 CDMO Leadership Award Champion in these categories.
Sponsored by Outsourced Pharma and Life Science Leader Magazine, the annual awards recognize the top contract development and manufacturing organizations (CDMOs) serving the pharmaceutical and biopharmaceutical industries.
There are six core categories: Capabilities, Compatibility, Expertise, Quality, Reliability and Service. Winners in these categories are judged by their customers as top performers. IDT Biologika has won a 2024 CDMO Leadership Award in each of the six categories in the group of respondents “Overall”, which combines Big and Small Pharma. In addition to that, IDT Biologika is one of the companies that scored one standard deviation or more above the weighted average in each of the core categories. Due to that, IDT is rated as 2024 CDMO Leadership Award Champion in these categories.
“Congratulations to our 2024 CDMO Leadership Award winners. By vote of your customers, you are recognized as the best in the global outsourcing development and manufacturing sector of the biopharma industry,” says Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma. “Award winners maintained and expanded capabilities and expertise to meet the needs of a diverse customer base; provided the additional quality and reliability so crucial to novel processes and products; and forged the closest relationships with customers. 2023 rang in with many unsettled questions. The 2024 CDMO Leadership Award winners are the support companies that best answered the bell over the past year.”
Dr. Jürgen Betzing, CEO IDT Biologika, will accept the 2024 CDMO Leadership Award on behalf of the company. He says: “The appreciation of our customers encourages us on our path to drive medical progress, not only in the field of vaccines, but especially in cell and gene therapy for the treatment of life-threatening diseases. We support our customers not only in the area of manufacturing, but also with our expertise in process development, cell lines and analytical development. It is an impressive confirmation that IDT Biologika meets the high demands of customers at all levels, especially in terms of expertise and know-how or the services they require.”
IDT Biologika handles every step in process development, clinical trial material and commercial manufacturing, quality control and packaging processes and is specialized in the commercial production of viral vaccines, viral vectors for cell and gene therapeutics, and fill/finish of biologics at its FDA and EMA approved sites in Germany and the US.
Industry Standard Research (ISR) provided the primary market research data for the CDMO Leadership Awards. 98 contract manufacturers were assessed by 23 performance metrics in ISR’s annual Contract Manufacturing Quality Benchmarking survey. ISR evaluated winners based on real-world experiential data and feedback from decision makers who work with contract manufacturing suppliers on an outsourced project within the past 18 months. Kate Hammeke, Vice President, Industry Standard Research says: “These awards are based on experiential feedback and enable users of ISR’s market research to make data-driven decisions with respect to choosing an outsourcing partner. It also means the winners of these awards have been delivering the highest quality of service according to their current and recent customers and are deserving of these accolades for their distinction.” For more information about the awards, visit:All our awards